Celularity Inc. - Class A Common Stock — Balance Sheet (NASDAQ:CELU) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 292.16 M414.13 M401.07 M143.89 M132.68 M107.33 M Total liabilities 14.22 M314.71 M202.16 M102.93 M123.84 M145.39 M Total equity 5 M99.42 M198.9 M40.96 M8.84 M-38.06 M Total liabilities & shareholders' equities 292.16 M414.13 M401.07 M143.89 M132.68 M107.33 M Total debt —————— Net debt ——————

News

NEXGEL discloses $15M upfront payment for Celularity portfolio

NexGel to license, acquire regenerative biomaterial products

Celularity licenses biomaterials portfolio for up to $35 million

Celularity names John Sprague acting CFO following executive departure

Celularity receives $12.2 million from sale of tax credits

Celularity stock drops after CMS withdraws skin substitute LCDs

Medicare withdraws skin substitute coverage changes set for 2026

Celularity secures $10 million financing from DoubleLine co-founder

Celularity secures up to $12 million in financing for longevity focus

Celularity’s diabetic foot ulcer therapy shows promise in clinical trial

Celularity stock rating upgraded to Buy by WBB Securities on CMS reimbursement changes

Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results - Celularity (NASDAQ:CELU), CARISMA Therapeutics (NASDAQ:CARM)